Home
This site is intended for healthcare professionals

Advanced Prostate Cancer: Latest Clinical Trials to Treatment Plans

12th Jun 2024
11:30pm - 12:45am (GMT)
12th - 13th Jun 2024
11:30pm - 12:45am (GMT)
Hosted on MedAll
Attendance certificate available
This event has ended. Similar events
Free
ONLINE

Description

This program is funded by an independent grant from Merck. This online education program has been designed solely for healthcare professionals in the USA. The content is not available for healthcare professionals in any other country.

Join our global experts for this accredited CME course on Advanced Prostate Cancer. The course is presented by leading Urology & Oncology experts, integrating the latest clinical insights into monotherapy and combination treatments for advanced prostate cancer. Discover emerging treatments from clinical trials and learn to integrate them into current protocols, enhancing your everyday practice with evidence-based advancements.

Stay informed about the latest & emerging therapies from clinical trials

Explore new treatments and how they can be incorporated into existing treatment protocols. Optimize patient care by utilizing the most advanced and effective treatment options available, ensuring that you deliver the best possible outcomes to your patients.

Plan for the clinical implementation of treatment regimens across a variety of healthcare settings

Participants will develop strategies to ensure that up-to-date treatment protocols are applied effectively in community, rural, hospital, and academic settings. The course will address how to identify and overcome potential barriers to the implementation of new treatments, with the goal of ensuring that all physicians, regardless of their location, have access to these advancements. This will enhance the quality and consistency of care provided to patients with advanced prostate cancer.

Facilitate patient-centered communication throughout the management journey

Hone your skills in articulating clinical data to patients and their families, aiding their understanding of the available therapies. Foster an environment that supports shared decision-making, ensuring that patients are well-informed about new treatment options and actively involved in their care decisions. This approach is designed to empower patients and enhance the effectiveness of their treatment journey.

Who is this course for

This online education program has been designed solely for healthcare professionals in the USA. The course provides continuing education for:

âś… Urologists

âś… Radiation oncologists

âś… Medical oncologists

âś… Clinical oncologists

âś… Urologic oncologists

âś… Pathologists

âś… Genetic testing experts

âś… Nuclear medicine physicians

âś… Family Physicians

âś… Physicians

âś… Physician Assistants

âś… Nurse Practitioners

âś… Other Health Professionals

Faculty

Professor Dakim Gaines

Professor Dakim Gaines is an Assistant Professor of Radiation Oncology at the Vanderbilt-Ingram Cancer Center. He earned his M.D./Ph.D. from Rutgers University after studying molecular biology at St. Mary's College of Maryland. Dr. Gaines completed his residency at Vanderbilt University Medical Center, engaging in the ABR Holman Pathway to research immunologic responses in kidney cancer post-SBRT. He specializes in genitourinary cancers and palliative radiotherapy and has been honored with multiple awards, including the 2021 ECOG-ACRIN Minority Scholarship Award.

Professor Shawn Dason

Professor Dason specializes in surgical treatments for a range of cancers, including those of the prostate, kidney, and bladder, employing advanced techniques such as robotic and laparoscopic surgery. His practice is deeply rooted in understanding patient needs, tailoring care plans to individual goals, and ensuring clarity in communication about disease and treatment paths. Beyond surgery, Professor Dason is an advocate for multidisciplinary care and considers alternative treatments when they offer better outcomes. As an assistant professor in the Department of Urology at The Ohio State University College of Medicine, he contributes significantly to the field through both teaching and research. Recognized for his contributions, particularly in bladder cancer genomics, Professor Dason has received national awards and has an extensive publication record. His work at The James signifies a commitment to excellence in patient care, education, and research at one of the country's foremost cancer centers.

Jeremy Patch, Director of Patient Programs at ZERO Prostate Cancer

For more than 25 years, ZERO Prostate Cancer has helped people and families impacted by prostate cancer. Jeremy Patch, ZERO's Director of Patient Programs & Education, brings a wealth of experience from the nonprofit and public health sectors to his role. Based in St. Louis, he has a history of leadership in cancer-focused nonprofits, including a notable stint at Susan G. Komen. With a B.A. in Psychology from Truman State University and an MPH from Saint Louis University, Jeremy has dedicated himself to public health, focusing on grantmaking, community needs assessment, and educational initiatives in oncology. At ZERO, he is driven by the goal to support cancer patients and families, aiming to reduce the impact of prostate cancer.

Faculty, planners, and staff disclosure information

Current Concepts Institute/MedAll staff and the planners and reviewers of this educational activity have no relevant financial or non-financial interests to disclose.

Shawn Dason, Dakim Gaines & Jeremy Patch have no relevant financial or non-financial interests to disclose.​

Andrew Laccetti has research contracts with ESSA and Bayer. He has received research funding from Johnson & Johnson. He is on a steering committee for Bayer. He has provided consulting for Guidepoint & Musculo. He has Stock options in Musculo​

Unapproved and/or off-label use disclosure

Current Concepts Institute/MedAll requires CE faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and

2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Accreditation statement

AMA PRA Category 1 Credits™ are available for this activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Current Concepts Institute and MedAll Education. Current Concepts Institute is accredited by the ACCME to provide continuing medical education for physicians.

Current Concepts Institute designates this online activity a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

This continuing education activity is active starting June 5 2024 and will expire on June 5 2025. Estimated time to complete this activity: 1.25 hours.

Learning objectives

  1. Evaluate the clinical utility of emerging therapies from clinical trial data and experiential practice

  2. Facilitate patient-centered communication throughout the management journey

  3. Plan for clinical implementation of treatment regimens for advanced prostate cancer across diverse healthcare settings

183 people attended this event. Sign up today and join your colleagues at future events.
View all

Similar events and on demand videos

 
12th - 13th Jun 2024
11:30pm - 12:45am (GMT)
Hosted on MedAll
Attendance certificate available
This event has ended. Similar events
Free
ONLINE